Table 2.
Study Group | Total | ||||
70 to 75 years | > 75 years | ||||
80 mg/m2 (n = 15) | 90 mg/m2 (n = 14) | 60 mg/m2 (n = 7) | 70 mg/m2 (n = 8) | (n = 44) | |
Treatment administered | |||||
Chemotherapy cycles | |||||
No. | 46 | 42 | 14 | 23 | 125 |
Median (range) | 2 (1 to 4) | 2 (1 to 5) | 3 (1 to 5) | 3 (1 to 6) | 3 (1 to 6) |
Vinorelbine (median, mg/m2/wk) | 8.6 | 8.8 | 9.4 | 10.3 | 8.9 |
Cisplatin (median, mg/m2/wk) | 13.6 | 15.9 | 11.2 | 14.4 | 14.5 |
Efficacy | |||||
Complete response | - | - | - | 1 | 1 |
Partial response | 8 | 8 | 2 | 3 | 21 |
Stable disease | 4 | 4 | 3 | 2 | 13 |
Progressive disease | 2 | 1 | - | - | 3 |
Not evaluated | 1 | 1 | 2 | 2 | 6 |
Overall response rate (%) | 53 | 57 | 29 | 50 | 50 |
Time to progression (median, in weeks) | 25.0 | 23.0 | 15.7 | 18.4 | 27.0 |
Overall Survival | |||||
Median (weeks) | 31.0 | 17.3 | 26.6 | 31.7 | 30.1 |
1-year (%) | 40.0 | 35.7 | 28.5 | 37.5 | 36.3 |